v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)    
Revenue $ 840,354 $ 0
Cost of goods sold 561,484 0
Gross profit 278,870 0
Operating expenses:    
Research and development 215,134 207,334
Selling, general and administrative 5,878,546 3,517,490
Total operating expenses 6,093,680 3,724,824
Loss from operations (5,814,810) (3,724,824)
Other income (expense):    
Foreign exchange transaction loss (24,343) (935)
Change in fair value of convertible notes payable (953,710) 0
Change in fair value of share liability (218,000) 110,285
Interest income 12,188 396
Interest expense (13,788) 0
Total other (expense) income (1,197,653) 109,746
Loss before income tax expense (7,012,463) (3,615,078)
Income tax provision 47,619 0
Net loss before allocation to noncontrolling interests (6,964,844) (3,615,078)
Less: Net loss attributable to noncontrolling interests (16,759) 0
Net loss attributable to ASP Isotopes Inc. shareholders $ (6,948,085) $ (3,615,078)
Net loss per share attributable to ASP Isotopes Inc. shareholders, basic and diluted $ (0.16) $ (0.12)
Weighted average shares of common stock outstanding, basic and diluted 44,561,844 29,141,525
Comprehensive loss    
Net loss before allocation to noncontrolling interests $ (6,964,844) $ (3,615,078)
Foreign currency translation (543,729) (1,003,853)
Total comprehensive loss before allocation to noncontrolling interests (7,508,573) (4,618,931)
Less: Comprehensive loss attributable to noncontrolling interests (7,530) 0
Comprehensive loss attributable to ASP Isotopes Inc. $ (7,501,043) $ (4,618,931)

Source